Enveric Biosciences, Inc.ENVBEarnings & Financial Report
Enveric Biosciences, Inc. is a clinical-stage biotechnology company developing novel therapeutics derived from cannabinoids and related molecules. Its product pipeline addresses unmet needs in mental health disorders including anxiety, depression, and treatment-resistant conditions, as well as adverse effects linked to cancer treatment. It operates mainly in North American and European biopharmaceutical markets, partnering with research institutes to advance candidates for underserved patient groups.
Revenue
$-35
Gross Profit
N/A
Operating Profit
$-1.9M
Net Profit
$-1.9M
Gross Margin
N/A
Operating Margin
5422660.0%
Net Margin
5369697.1%
YoY Growth
-103.8%
EPS
$-3.72
Enveric Biosciences, Inc. Q2 FY2024 Financial Summary
Enveric Biosciences, Inc. reported revenue of $-35 (down 103.8% YoY) for Q2 FY2024, with a net profit of $-1.9M (up 70.4% YoY) (5369697.1% margin).
Key Financial Metrics
| Total Revenue | $-35 |
|---|---|
| Net Profit | $-1.9M |
| Gross Margin | N/A |
| Operating Margin | 5422660.0% |
| Report Period | Q2 FY2024 |
Enveric Biosciences, Inc. Annual Revenue by Year
Enveric Biosciences, Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $3.7K).
| Year | Annual Revenue |
|---|---|
| 2023 | $3.7K |
Enveric Biosciences, Inc. Quarterly Revenue & Net Profit History
Enveric Biosciences, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $-250 | -11.1% | N/A | N/A |
| Q2 FY2025 | $-132 | -277.1% | $-2.5M | 1908470.5% |
| Q4 FY2024 | $-225 | -139.8% | N/A | N/A |
| Q3 FY2024 | $-217 | -109.7% | $-2.1M | 960383.4% |
| Q2 FY2024 | $-35 | -103.8% | $-1.9M | 5369697.1% |
| Q4 FY2023 | $566 | — | N/A | N/A |
| Q3 FY2023 | $2.2K | +826.3% | $-2.8M | -126160.8% |
| Q2 FY2023 | $916 | +237.1% | $-6.4M | -693892.2% |
Income Statement
| Q2 2023 | Q3 2023 | Q4 2023 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $916 | $2237 | $566 | $-35 | $-217 | $-225 | $-132 | $-250 |
| YoY Growth | 237.1% | 826.3% | N/A | -103.8% | -109.7% | -139.8% | -277.1% | -11.1% |
Balance Sheet
| Q2 2023 | Q3 2023 | Q4 2023 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $9.8M | $6.6M | $4.3M | $6.1M | $4.8M | $3.1M | $3.5M | $5.1M |
| Liabilities | $4.9M | $4.2M | $2.3M | $645340 | $839166 | $1.5M | $1.4M | $918400 |
| Equity | $4.9M | $2.4M | $2.0M | $5.4M | $4.0M | $1.6M | $2.2M | $4.2M |
Cash Flow
| Q2 2023 | Q3 2023 | Q4 2023 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-4.5M | $-2.7M | $-1.8M | $-2.9M | $-927070 | $-1.3M | $-1.9M | $-1.8M |